First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
To equip them with the latest knowledge and skills to handle patients coming to them in a better way
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
The partnership will capitalize on the combined capabilities of the two organizations
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Several late-stage pipeline products have the potential to address some of these unmet needs
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Subscribe To Our Newsletter & Stay Updated
